CA2798214C - Vaccine against beta-herpesvirus infection and use thereof - Google Patents

Vaccine against beta-herpesvirus infection and use thereof Download PDF

Info

Publication number
CA2798214C
CA2798214C CA2798214A CA2798214A CA2798214C CA 2798214 C CA2798214 C CA 2798214C CA 2798214 A CA2798214 A CA 2798214A CA 2798214 A CA2798214 A CA 2798214A CA 2798214 C CA2798214 C CA 2798214C
Authority
CA
Canada
Prior art keywords
vaccine against
herpesvirus infection
against beta
beta
herpesvirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2798214A
Other languages
English (en)
French (fr)
Other versions
CA2798214A1 (en
Inventor
Christian Thirion
Ulrich Koszinowski
Christian A. Mohr
Zsolt Ruzsics
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA3128572A priority Critical patent/CA3128572C/en
Publication of CA2798214A1 publication Critical patent/CA2798214A1/en
Application granted granted Critical
Publication of CA2798214C publication Critical patent/CA2798214C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material
    • C12N2710/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16161—Methods of inactivation or attenuation
    • C12N2710/16162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16511—Roseolovirus, e.g. human herpesvirus 6, 7
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2798214A 2010-05-05 2011-05-05 Vaccine against beta-herpesvirus infection and use thereof Active CA2798214C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3128572A CA3128572C (en) 2010-05-05 2011-05-05 Vaccine against beta-herpesvirus infection and use thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10004751 2010-05-05
EP10004751.3 2010-05-05
EP10005045.9 2010-05-12
EP10005045 2010-05-12
PCT/EP2011/002252 WO2011138040A2 (en) 2010-05-05 2011-05-05 Vaccine against beta-herpesvirus infection and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3128572A Division CA3128572C (en) 2010-05-05 2011-05-05 Vaccine against beta-herpesvirus infection and use thereof

Publications (2)

Publication Number Publication Date
CA2798214A1 CA2798214A1 (en) 2011-11-10
CA2798214C true CA2798214C (en) 2021-10-19

Family

ID=44146744

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2798214A Active CA2798214C (en) 2010-05-05 2011-05-05 Vaccine against beta-herpesvirus infection and use thereof
CA3128572A Active CA3128572C (en) 2010-05-05 2011-05-05 Vaccine against beta-herpesvirus infection and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3128572A Active CA3128572C (en) 2010-05-05 2011-05-05 Vaccine against beta-herpesvirus infection and use thereof

Country Status (8)

Country Link
US (3) US9078867B2 (enExample)
EP (1) EP2566957B8 (enExample)
JP (2) JP2013527758A (enExample)
AU (1) AU2011250191A1 (enExample)
CA (2) CA2798214C (enExample)
ES (1) ES2679245T3 (enExample)
SG (2) SG10201503450WA (enExample)
WO (1) WO2011138040A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
TR201802741T4 (tr) * 2010-05-14 2018-03-21 Univ Oregon Health & Science Rekombinant hcmv ve rhcmv vektörleri ve bunların kullanımları.
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
EP2766385A2 (en) * 2011-10-12 2014-08-20 Novartis AG Cmv antigens and uses thereof
US20130156808A1 (en) * 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
LT2964769T (lt) * 2013-03-05 2018-12-10 Oregon Health & Science University Citomegalo viruso vektoriai, leidžiantys kontroliuoti ląstelių nukreipimą į taikinį
US20160243216A1 (en) 2013-10-29 2016-08-25 The University Of Sydney Cmv immuno-stimulatory composition
EA039174B1 (ru) 2014-07-16 2021-12-14 Орегон Хелс Энд Сайенс Юниверсити Цитомегаловирус человека, содержащий гетерологичный антиген, способ его получения, полинуклеотид, клетка, композиция и способ индуцирования иммунного ответа (варианты)
SG11201706454VA (en) 2015-02-10 2017-09-28 Univ Oregon Health & Science Methods and compositions useful in generating non canonical cd8+ t cell responses
MA43285A (fr) 2015-11-20 2018-09-26 Univ Oregon Health & Science Vecteurs cmv comprenant des éléments de reconnaissance des microarn
MX2019004518A (es) 2016-10-18 2019-06-17 Univ Oregon Health & Science Vectores de citomegalovirus que provocan celulas t restringidas por moleculas del complejo mayor de histocompatibilidad e.
US11617788B2 (en) 2018-07-09 2023-04-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Viral promoters and compositions and methods of use thereof
MA53158A (fr) * 2018-07-20 2021-05-26 Aicuris Gmbh & Co Kg Procédés de criblage et d'identification d'agents inhibant ou modulant le complexe de sortie nucléaire du virus de l'herpès
US20230364215A1 (en) * 2020-10-02 2023-11-16 Colorado State University Research Foundation Compositions comprising inactivated microbes, and methods for use and production thereof
CN116042526B (zh) * 2022-07-04 2023-11-10 北京肿瘤医院(北京大学肿瘤医院) P16基因特异性甲基化的正常人永生化结肠成纤维细胞

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7374768B1 (en) 1990-09-25 2008-05-20 Xenova Research Limited Viral vaccines
DE19733364A1 (de) * 1997-08-01 1999-02-04 Koszinowski Ulrich H Prof Verfahren zur Klonierung eines großen Virusgenoms
US6573090B1 (en) 1998-12-09 2003-06-03 The General Hospital Corporation Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors
WO2005012545A2 (en) 2003-07-25 2005-02-10 The Regents Of The University Of California Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors
CA2837748C (en) * 2004-05-25 2016-03-08 Oregon Health And Science University Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors

Also Published As

Publication number Publication date
US20150306210A1 (en) 2015-10-29
WO2011138040A2 (en) 2011-11-10
EP2566957A2 (en) 2013-03-13
EP2566957B8 (en) 2018-06-06
EP2566957B1 (en) 2018-04-18
US20190117766A1 (en) 2019-04-25
CA2798214A1 (en) 2011-11-10
US10842863B2 (en) 2020-11-24
CA3128572C (en) 2023-02-21
JP2013527758A (ja) 2013-07-04
AU2011250191A1 (en) 2012-11-22
ES2679245T3 (es) 2018-08-23
US20130202638A1 (en) 2013-08-08
WO2011138040A3 (en) 2012-10-26
SG185121A1 (en) 2012-11-29
JP6427514B2 (ja) 2018-11-21
US9078867B2 (en) 2015-07-14
SG10201503450WA (en) 2015-06-29
WO2011138040A8 (en) 2012-12-20
JP2016136950A (ja) 2016-08-04
CA3128572A1 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
CA2798214C (en) Vaccine against beta-herpesvirus infection and use thereof
USD659044S1 (en) Dial
CA144130S (en) Cord clip
PH12013500065A1 (en) Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
CA137617S (en) Bottle
KR20180085042A (ko) 농업, 산업 및 다른 용도를 위한 방부제로서 비스무트-티올
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
TW201144301A (en) Processes for preparing linezolid
MY168166A (en) Polymer and Composition Including Same, and Adhesive Composition
IL259652B (en) A bacterial strain, a composition comprising thereof and its uses
IN2012DN03379A (enExample)
AU2011347268A8 (en) Recombinant Mycobacterium as a vaccine
UA112760C2 (uk) Теобромін у комбінації з гвайфенезином для лікування кашлю
IN2014DN10669A (enExample)
AU2011298391A8 (en) Substituted N-phenethyltriazoloneacetamides and uses thereof
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
WO2014102343A8 (en) Variant of bpifb4 protein
PH12014502326B1 (en) A composition compromising amlodipine and losartan having an improved stability
IN2015DN00962A (enExample)
MX2011011180A (es) Compuestos que tienen efecto fisiologico.
AU2011254057A1 (en) Nail polish ring
GB201106162D0 (en) Combination vaccine
HK1181671A (en) Use of 1h-quinazoline-2,4-diones
UA35660U (en) Use of antihomotoxic preparations as cytoprotectors
UA94339C2 (ru) применение корвитина в качестве средства фригопротекторного действия

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160419